Soleno Therapeutics (NASDAQ:SLNO) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.
The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges. Soleno has completed multiple clinical trials of DCCR in adults and adolescents with PWS, evaluating its effects on hyperphagia, body composition and metabolic parameters. In addition to PWS, Soleno is advancing a proprietary formulation called SEZ982 for the treatment of phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare inherited condition that leads to multi-systemic impairment due to deficient protein glycosylation.
Since its inception, Soleno has built a development pipeline rooted in rigorous translational research and active engagement with patient advocacy communities. The company works closely with academic collaborators and clinical centers of excellence across North America and Europe to design studies that address the full spectrum of disease manifestations. Soleno’s team combines expertise in drug formulation, clinical trial execution and regulatory strategy to expedite the path from laboratory discovery to potential market approval.
Led by an experienced management team with deep backgrounds in biotech development and commercialization, Soleno continues to expand its scientific capabilities and prepare for potential regulatory submissions. The company maintains strategic partnerships and seeks to broaden its portfolio by identifying additional rare disease opportunities where small‐molecule therapies can deliver meaningful clinical outcomes. Through a patient-focused model, Soleno aims to bring new treatment options to communities with high unmet medical needs.
